GSK.L

$1950.50-5.50 (-0.28%)

Market ClosedAs of Mar 20, 6:07 PM UTC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1950.50
Potential Upside
90%
Whystock Fair Value$3706.02
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$78.08B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.03
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Strong income play. Yield provides a meaningful total return floor.
369.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
43.31%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.50

Recent News

Zacks
Mar 20, 2026

Theravance's Q4 Earnings and Revenues Miss Estimates

TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 20, 2026

Assessing GSK (LSE:GSK) Valuation As Pipeline Momentum Meets Recent Share Price Pullback

Recent share performance and context GSK (LSE:GSK) has recently seen mixed share performance, with a 0.8% decline over the past day and a 3.7% fall over the past week, while remaining positive over the past year. See our latest analysis for GSK. The recent weakness in GSK’s 1 month share price return of 12.6% contrasts with its 90 day gain of 7.4% and 1 year total shareholder return of 34.7%. This suggests that longer term momentum remains stronger than the latest pullback. If you are...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 19, 2026

Here's Why GSK (GSK) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Benzinga
Mar 18, 2026

Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report

Amgen Inc. and GSK plc are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. This move will augment the total number of discounted prescription medications available on the platform to 54, from five different pharmaceutical companies, according to a report by FOX Business on Friday. Amgen will offer an 80% discount on Amjevita, a medication used for rheumatoid arthritis, psoriasis, and ulcerative colitis

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults

GSK secures FDA approval to expand Arexvy's use to high-risk adults aged 18-49 years, broadening access as the company pushes wider global adoption.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.